Detection of FLT3 Gene and FLT3/ITD Mutation by Polymerase Chain Reaction-single-strand Conformation Polymorphism in Patients with Acute Lymphoblastic Leukemia
Overview
Authors
Affiliations
Objective: To analyze Fms-like tyrosine kinase 3 (FLT3) gene and FLT3 internal tandem duplication (ITD) mutation in acute lymphoblastic leukemia (ALL) patients of different immunological subtypes.
Methods: Polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) was used to detect FLT3 gene and FLT3/ITD mutation in 63 ALL cases.
Results: Among the 63 ALL cases, FLT3 gene was detected in 41 (61.5%) cases. The positivity rate of FLT3 gene in pre-pre B-lineage ALL, pre-B-ALL, B-lineage ALL and T-lineage ALL cases were 93.3% (14/15), 77.8% (14/18), 41.7% (5/12) and 28.6% (4/14), respectively. The positivity rate of FLT3 gene was significantly higher in pre-pre B-ALL/pre B-ALL subtypes (84.8%) than in B-ALL subtypes (41.7%, P<0.005), and the rate was significantly higher in B-ALL subtypes (73.3%) than in T-ALL subtypes (28.6%, P<0.001). Two cases (3.2%) were found to have FLT3/ITD mutation, which were also positive for myeloid antigen expression and diagnosed as acute mixed-lineage leukemia, showing leukocytosis and high percentage of bone marrow blast cells with poor prognosis.
Conclusions: FLT3 gene can be detected in both B-and T-lineage ALL patients, but more frequently in the former. In B-lineage ALL patients, FLT3 gene is more frequent in cases with undifferentiated than those with differentiated blast cells. FLT3/ITD is rarely detected in ALL patients and FLT3/ITD mutation detection might be helpful to identify the genotypes and evaluate the prognosis of acute leukemia.
Identification of FLT3 and NPM1 Mutations in Patients with Acute Myeloid Leukaemia.
Yusoff Y, Seman Z, Othman N, Kamaluddin N, Esa E, Zulkiply N Asian Pac J Cancer Prev. 2019; 20(6):1749-1755.
PMID: 31244296 PMC: 7021611. DOI: 10.31557/APJCP.2019.20.6.1749.
Cytogenetic Profile and Gene Mutations of Childhood Acute Lymphoblastic Leukemia.
Alkhayat N, Elborai Y, Al Sharif O, Shahrani M, Alsuhaibani O, Awad M Clin Med Insights Oncol. 2017; 11:1179554917721710.
PMID: 28811744 PMC: 5528943. DOI: 10.1177/1179554917721710.
Elyamany G, Awad M, Alsuhaibani O, Fadalla K, Al Sharif O, Shahrani M Mediterr J Hematol Infect Dis. 2014; 6(1):e2014038.
PMID: 24959335 PMC: 4063605. DOI: 10.4084/MJHID.2014.038.
Neumann M, Heesch S, Gokbuget N, Schwartz S, Schlee C, Benlasfer O Blood Cancer J. 2012; 2(1):e55.
PMID: 22829239 PMC: 3270253. DOI: 10.1038/bcj.2011.49.